Targeting a key FAK-tor: the therapeutic potential of combining focal adhesion kinase (FAK) inhibitors and chemotherapy for chemoresistant non-small cell lung cancer.

Autor: Geijerman E; Amsterdam University College, Amsterdam, The Netherlands., Terrana F; Department of Medical Oncology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.; Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche (STEBICEF), Università degli Studi di Palermo, Palermo, Italy., Peters GJ; Department of Medical Oncology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.; Department of Biochemistry, Medical University of Gdansk, Gdańsk, Poland., Deng D; Department of Preventive Dentistry, Academic Center for Dentistry Amsterdam (ACTA), University of Amsterdam and Vrije Universiteit Amsterdam, Amsterdam, The Netherlands., Diana P; Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche (STEBICEF), Università degli Studi di Palermo, Palermo, Italy., Giovannetti E; Department of Medical Oncology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.; Fondazione Pisana per la Scienza, Pisa, Italy., Xu G; Department of Medical Oncology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.

Publikováno v: Expert opinion on investigational drugs [Expert Opin Investig Drugs] 2024 Nov; Vol. 33 (11), pp. 1103-1118. Date of Electronic Publication: 2024 Oct 22.

Nuclear Focal Adhesion Kinase Protects against Cisplatin Stress in Ovarian Carcinoma.

Autor: Zhang Y; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, University of California, San Diego, La Jolla, California., Ojalill M; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, University of California, San Diego, La Jolla, California., Boyer A; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, University of California, San Diego, La Jolla, California., Chen XL; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, University of California, San Diego, La Jolla, California., Tahon E; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, University of California, San Diego, La Jolla, California., Thivolle Lioux G; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, University of California, San Diego, La Jolla, California., Xia M; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, University of California, San Diego, La Jolla, California., Abbas M; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, University of California, San Diego, La Jolla, California., Soylu HM; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, University of California, San Diego, La Jolla, California., Flieder DB; Fox Chase Cancer Center, Philadelphia, Pennsylvania., Connolly DC; Fox Chase Cancer Center, Philadelphia, Pennsylvania., Molinolo AA; Department of Pathology, Moores Cancer Center, University of California San Diego, La Jolla, California., McHale MT; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, University of California, San Diego, La Jolla, California., Stupack DG; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, University of California, San Diego, La Jolla, California., Schlaepfer DD; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Sciences, Moores Cancer Center, University of California, San Diego, La Jolla, California.

Publikováno v: Cancer research communications [Cancer Res Commun] 2024 Dec 01; Vol. 4 (12), pp. 3165-3179.

MYO6 contributes to tumor progression and enzalutamide resistance in castration-resistant prostate cancer by activating the focal adhesion signaling pathway.

Autor: Zheng, Shengfeng^1,2,3,4 (AUTHOR), Hong, Zhe^1,2,3 (AUTHOR) hz_urology@shca.org.cn, Tan, Yao^1,2,5 (AUTHOR), Wang, Yue^1,2,3 (AUTHOR), Li, Junhong^1,2,3 (AUTHOR), Zhang, Zihao^1,2,3 (AUTHOR), Feng, Tao^1,2,3 (AUTHOR), Hong, Zongyuan⁶ (AUTHOR) zyhong@wnmc.edu.cn, Lin, Guowen^1,2,3 (AUTHOR) guowenlin@urocancer.org, Ye, Dingwei^1,2,3 (AUTHOR) dwyeli@163.com

Publikováno v: Cell Communication & Signaling. 10/24/2024, Vol. 22 Issue 1, p1-18. 18p.

Acidic preconditioning induced intracellular acid adaptation to protect renal injury via dynamic phosphorylation of focal adhesion kinase-dependent activation of sodium hydrogen exchanger 1.

Autor: Chen, Annan¹ (AUTHOR), Zhang, Jian¹ (AUTHOR), Yan, Zhixin¹ (AUTHOR), Lu, Yufei¹ (AUTHOR), Chen, Weize¹ (AUTHOR), Sun, Yingxue¹ (AUTHOR), Gu, Qiuyu¹ (AUTHOR), Li, Fang¹ (AUTHOR), Yang, Yan¹ (AUTHOR), Qiu, Shanfang² (AUTHOR), Lin, Xueping² (AUTHOR), Zhang, Dong² (AUTHOR), Teng, Jie^1,2 (AUTHOR), Fang, Yi¹ (AUTHOR), Shen, Bo^1,3 (AUTHOR) shen.bo@zs-hospital.sh.cn, Song, Nana^1,3,4 (AUTHOR) song.nana@zs-hospital.sh.cn, Ding, Xiaoqiang^1,3 (AUTHOR) ding.xiaoqiang@zs-hospital.sh.cn

Publikováno v: Cell Communication & Signaling. 8/8/2024, Vol. 22 Issue 1, p1-21. 21p.

Development of novel focal adhesion kinase (FAK) inhibitors for targeting cancer: Structural insights and therapeutic potential.

Autor: Li Y; Department of Respiratory and Critical Care Medicine, Targeted Tracer Research and Development Laboratory, Institute of Respiratory Health, Neuro-system and Multimorbidity Laboratory, State Key Laboratory of Biotherapy and Cancer Center and State Key Laboratory of Respiratory Health and Multimorbidity, West China Hospital, Sichuan University, 610041, Sichuan, China., Zhang Y; Department of Respiratory and Critical Care Medicine, Targeted Tracer Research and Development Laboratory, Institute of Respiratory Health, Neuro-system and Multimorbidity Laboratory, State Key Laboratory of Biotherapy and Cancer Center and State Key Laboratory of Respiratory Health and Multimorbidity, West China Hospital, Sichuan University, 610041, Sichuan, China; West China College of Medicine, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China., Zhang J; Department of Respiratory and Critical Care Medicine, Targeted Tracer Research and Development Laboratory, Institute of Respiratory Health, Neuro-system and Multimorbidity Laboratory, State Key Laboratory of Biotherapy and Cancer Center and State Key Laboratory of Respiratory Health and Multimorbidity, West China Hospital, Sichuan University, 610041, Sichuan, China., Zhan Z; Department of Respiratory and Critical Care Medicine, Targeted Tracer Research and Development Laboratory, Institute of Respiratory Health, Neuro-system and Multimorbidity Laboratory, State Key Laboratory of Biotherapy and Cancer Center and State Key Laboratory of Respiratory Health and Multimorbidity, West China Hospital, Sichuan University, 610041, Sichuan, China. Electronic address: zxzhan@scu.edu.cn., Mao W; Department of Respiratory and Critical Care Medicine, Targeted Tracer Research and Development Laboratory, Institute of Respiratory Health, Neuro-system and Multimorbidity Laboratory, State Key Laboratory of Biotherapy and Cancer Center and State Key Laboratory of Respiratory Health and Multimorbidity, West China Hospital, Sichuan University, 610041, Sichuan, China. Electronic address: wuyanmao1@sina.com.

Publikováno v: European journal of medicinal chemistry [Eur J Med Chem] 2024 Dec 05; Vol. 279, pp. 116913. Date of Electronic Publication: 2024 Sep 26.